PMID- 27011200
OWN - NLM
STAT- MEDLINE
DCOM- 20161107
LR  - 20220330
IS  - 1999-4915 (Electronic)
IS  - 1999-4915 (Linking)
VI  - 8
IP  - 3
DP  - 2016 Mar 22
TI  - Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel 
      Virotherapeutic Strategies.
PG  - 85
LID - 10.3390/v8030085 [doi]
LID - 85
AB  - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative 
      potential for many hematologic malignancies and blood diseases. However, the 
      success of allo-HSCT is limited by graft-versus-host disease (GVHD), an 
      immunological syndrome that involves inflammation and tissue damage mediated by 
      donor lymphocytes. Despite immune suppression, GVHD is highly incident even after 
      allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, 
      alternative and more effective therapies are needed to prevent or control GVHD 
      while preserving the beneficial graft-versus-cancer (GVC) effects against 
      residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as 
      myxoma virus (MYXV) are receiving increased attention due to their dual role in 
      controlling GVHD while preserving or augmenting GVC. This review focuses on the 
      molecular basis of GVHD, as well as state-of-the-art advances in developing novel 
      therapies to prevent or control GVHD while minimizing impact on GVC. Recent 
      literature regarding conventional and the emerging therapies are summarized, with 
      special emphasis on virotherapy to prevent GVHD. Recent advances using 
      preclinical models with oncolytic viruses such as MYXV to ameliorate the 
      deleterious consequences of GVHD, while maintaining or improving the anti-cancer 
      benefits of GVC will be reviewed.
FAU - Villa, Nancy Y
AU  - Villa NY
AD  - Division of Hematology and Oncology, Department of Medicine, University of 
      Florida, Gainesville, FL 32610, USA. nancy.villa@medicine.ufl.edu.
FAU - Rahman, Masmudur M
AU  - Rahman MM
AD  - Department of Molecular Genetics and Microbiology, University of Florida, 
      Gainesville, FL 32610, USA. masmudur@ufl.edu.
FAU - McFadden, Grant
AU  - McFadden G
AD  - Department of Molecular Genetics and Microbiology, University of Florida, 
      Gainesville, FL 32610, USA. grantmcf@ufl.edu.
FAU - Cogle, Christopher R
AU  - Cogle CR
AD  - Division of Hematology and Oncology, Department of Medicine, University of 
      Florida, Gainesville, FL 32610, USA. christopher.cogle@medicine.ufl.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160322
PL  - Switzerland
TA  - Viruses
JT  - Viruses
JID - 101509722
SB  - IM
MH  - Animals
MH  - Drug Evaluation, Preclinical
MH  - Graft vs Host Disease/physiopathology/*prevention & control/*therapy
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Myxoma virus/growth & development
MH  - Oncolytic Virotherapy/*methods
MH  - Transplantation, Homologous/adverse effects
PMC - PMC4810275
OTO - NOTNLM
OT  - GVC
OT  - GVHD
OT  - MYXV
OT  - allo-HSCT
OT  - allogeneic
OT  - cancer
OT  - hematopoietic cell transplant
EDAT- 2016/03/25 06:00
MHDA- 2016/11/08 06:00
PMCR- 2016/03/01
CRDT- 2016/03/25 06:00
PHST- 2015/12/28 00:00 [received]
PHST- 2016/03/09 00:00 [revised]
PHST- 2016/03/09 00:00 [accepted]
PHST- 2016/03/25 06:00 [entrez]
PHST- 2016/03/25 06:00 [pubmed]
PHST- 2016/11/08 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - v8030085 [pii]
AID - viruses-08-00085 [pii]
AID - 10.3390/v8030085 [doi]
PST - epublish
SO  - Viruses. 2016 Mar 22;8(3):85. doi: 10.3390/v8030085.